Clinical data | |
---|---|
Trade names | Korsuva, Kapruvia |
Other names | CR845, FE-202845, D-Phe-D-Phe-D-Leu-D-Lys-[γ-(4-N-piperidinyl)amino carboxylic acid][1] |
AHFS/Drugs.com | Monograph |
License data | |
Routes of administration | Intravenous[2] |
Drug class | Kappa opioid receptor agonist[2] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 100% (IV)[5] |
Metabolism | Not metabolized[5] |
Elimination half-life | 2 hours[5] |
Excretion | Excreted as unchanged drug via bile and urine[5] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C36H53N7O6 |
Molar mass | 679.863 g·mol−1 |
3D model (JSmol) |
|
| |
|
Difelikefalin, sold under the brand name Korsuva, is a medication used to in itchiness in those on hemodialysis due to chronic kidney disease.[4] It may be used in moderate to severe cases.[6] It is given by injection into a vein at the end of dialysis.[4]
Common side effects include diarrhea, dizziness, nausea, risk of falling, high potassium, headache, and sleepiness.[4] It should not be used in people with significant liver problems.[4] It is a kappa opioid receptor (KOR) agonist which binds to specific nerve and immune cells to decrease itching and inflammation.[2]
Difelikefalin was approved for medical use in the United States in 2021 and Europe in 2022.[4][2] In the United Kingdom it costs the NHS about £420 per vial as of 2022.[6] In the United States it costs about 2,000 USD per month.[7]
References edit
- ^ Janecka A, Perlikowska R, Gach K, Wyrebska A, Fichna J (2010). "Development of opioid peptide analogs for pain relief". Curr. Pharm. Des. 16 (9): 1126–35. doi:10.2174/138161210790963869. PMID 20030621.
- ^ a b c d e "Kapruvia EPAR". European Medicines Agency (EMA). 22 February 2022. Archived from the original on 6 May 2022. Retrieved 28 April 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ https://pdf.hres.ca/dpd_pm/00066996.PDF Archived 2022-10-01 at the Wayback Machine [bare URL PDF]
- ^ a b c d e f g h i "Korsuva- difelikefalin injection, solution". DailyMed. Archived from the original on 12 September 2021. Retrieved 12 September 2021.
- ^ a b c d Raymond S. Sinatra; Jonathan S. Jahr; J. Michael Watkins-Pitchford (14 October 2010). The Essence of Analgesia and Analgesics. Cambridge University Press. pp. 490–491. ISBN 978-1-139-49198-3.
- ^ a b "Difelikefalin". SPS - Specialist Pharmacy Service. 10 December 2015. Archived from the original on 24 October 2021. Retrieved 28 October 2022.
- ^ Watnick, Suzanne; Butler, Catherine R. (August 2022). "Difelikefalin: A Novel Therapy for Dialysis Patient Care". Kidney Medicine. 4 (8): 100519. doi:10.1016/j.xkme.2022.100519.